Loading...
Guest User
Welcome! Please login.
| IPO Listing At | NSE SME |
| SME IPO Issue Type | Fixed Price Issue |
| Total Issue Size | ₹10.85 Cr |
| Reserved for Market Maker | ₹0.00 Cr |
| Net Issue Size | ₹10.85 Cr |
| Fresh Issue | ₹10.30 Cr |
| Face Value | ₹10 Per Equity Share |
| Issue Price | ₹84.00 per share |
| Discount | Retail: 0.00 |
| NSE Code | SUNREST |
| Registrar | Skyline Financial Services Pvt.Ltd. |
| Lead Managers | Mark Corporate Advisors Pvt.Ltd. |
Disclaimer: GMP is sourced from grey market dealers and is indicative only. Always conduct your own due diligence.
* Allotment, Refund, Demat Credit & Listing dates are tentative and subject to change.
Minimum bid: 1,600 shares and in multiples thereof
Incorporated in 2017, Sunrest Lifescience Limited offers a diverse range of healthcare and personal care products.
The company's product range includes Capsules, Tablets, Syrup, Ointment, Gel, mouthwash, Solution, Suspension, Dry Powders, and Toothpaste. Sunrest Lifescience's product portfolio encompasses an extensive range of drugs such as Anti-Bacterial, Anti Diarrheal, AntiFungal, Anti Malerial, Anti Diabetic, Dental Cure, Anti Protozol, Anti Histamine, Anti-Hypertensive drugs, Cosmetic, Anti Parasitic, Multivitamin, Multimineral, Nutraceutical, and Anti-inflammatory.
The company gets its products manufactured by third-party pharma product manufacturers which also includes Trilend Pharmaceuticals Private Limited (Trilend), a Sunrest group company. The company has 43 third-party manufacturers across these states: Gujarat, Punjab, Maharashtra, Haryana, Himachal Pradesh, Uttarakhand and Madhya Pradesh.
Sunrest Lifescience's clientele includes stockists and Super Stockists & in turn, it is available at Chemist shops, Dispensaries, Hospitals, etc.
With 18 Registered Trademarks for 32 products, Sunrest Lifescience is committed to delivering high-quality products to its customers.
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Meeting Working Capital Requirements | 8.55 |
| 2 | General Corporate Purpose | 1.40 |
| Period Ended | 30 Jun 2023 | 31 Mar 2023 | 31 Mar 2022 | 31 Mar 2021 |
|---|---|---|---|---|
| Assets | 17.06 | 16.71 | 13.02 | 9.48 |
| Total Income | 5.64 | 24.67 | 26.91 | 16.95 |
| Profit After Tax | 0.75 | 2.04 | 0.78 | 0.17 |
| NET Worth | 3.87 | 3.12 | 1.07 | 0.29 |
| Reserves and Surplus | 0.87 | 0.12 | 1.06 | 0.28 |
| Total Borrowing | 3.47 | 2.14 | 3.24 | 2.32 |
| Amount in ₹ Crore | ||||
| KPI | |
|---|---|
| ROE | 53% |
| ROCE | 98% |
| Debt / Equity | 0.64% |
| RoNW | 65.59% |
| PAT Margin | 8.00% |
| Metric | Pre IPO | Post IPO |
|---|---|---|
| EPS (₹) | 6.81 | |
| P/E (x) | 12.33 | 12 |
| Promoter Holding | 100% | 69.91% |
| Market Cap | ₹36.05 Cr. | |
